1
Followers
7
Following
Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Next Generation Contact Lenses and Visual Prostheses Market is anticipated to grow at a CAGR 52% by 2030
Roots Analysis has done a detailed study on Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- Over 55 novel ophthalmic products are currently available / being developed for various therapeutic, diagnostic & monitoring and drug delivery applications; their growing popularity is evident across social media as well
- The current market landscape features both industry and non-industry players across the world, having proprietary products in different stages of development
- The introduction of bionic eyes has revolutionized the treatment landscape; with three products already in the market, several players are engaged in the development of such solutions
- Case Study: In order to increase the adoption of marketed products, companies have developed and implemented a diverse range of promotional strategies
- Partnership activity across the globe is indicative of the increasing interest of stakeholders in developing novel products for use in treating ophthalmic disorders
- In fact, close to 7,500 patents covering innovative contact lens technologies have been granted / filed in the given time period, significantly strengthening the intellectual capital in this domain
- A number of prominent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders
- The market is poised to grow at a steady pace as stakeholders tap the multi-billion potential in the coming decade; the opportunity is likely to be well distributed across various products, target indications and regions
- In the long term, the opportunity is likely to be segmented across diverse therapeutic modalities, immune checkpoint targets and routes of administration
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Context and Background
- An Overview of Contact Lenses
- Evolution of Contact Lenses
- Applications of Contact Lenses
- Types of Contact Lenses
- Classification of Contact Lenses
- Therapeutic Contact Lenses
- Drug-Eluting Contact Lenses
- Mechanism of Drug Delivery through Contact Lenses
- Techniques for Developing Drug-Eluting Contact Lenses
- Diagnostic / Monitoring Contact Lenses
- Visual Prostheses
- Architecture of a Bionic Eye
- Working of a Bionic Eye
- Key Therapeutic Indications
- Prevalent Trends and Future Perspectives
- MARKET OVERVIEW
- Chapter Overview
- Next Generation Contact Lenses: Overall Market Landscape
- Distribution by Type of Developer
- Distribution by Location of Headquarters of Developers
- Distribution by Status of Development
- Distribution by Target Indication
- Distribution by Type of Product
- Next Generation Contact Lenses: Market Landscape of Therapeutic Lenses
- Next Generation Contact Lenses: Market Landscape of Drug-Eluting Lenses
- Next Generation Contact Lenses: Market Landscape of Diagnostic / Monitoring Lenses
- Visual Prostheses: Overall Market Landscape
- Distribution by Type of Developer
- Distribution by Location of Headquarters of Developers
- Distribution by Status of Development
- Distribution by Target Indication
- Distribution by Implant Site
4.7 Geographical Distribution of Stakeholder Players and KOLs
- PROMOTIONAL ANALYSIS
- Chapter Overview
- An Overview of Channels Used for Promotional Campaigns
- Channels Adopted by Industry Players for Promotional Campaigns
- Product Website Analysis
- Product Brochure Analysis
- Product User Manual Analysis
- ChromaGen™: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Messages for Patients
- CUSTOMFLEX® ARTIFICIALIRIS: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Messages for Patients
- Other Messages
- Other Promotional Activities
- Publication in Journals
- EYEMATE®: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Messages for Patients
- Other Promotional Activities
- Publication in Journals
- Hyper-CL™: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Messages for Patients
- Product User Manual Analysis
- Other Messages
- Other Promotional Activities
- Publication in Journals
- Implantable Miniature Telescope: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Patient Access Program
- Other Messages
- Product User Manual Analysis
- Messages for Patients
- Other Promotional Activities
- Publication in Journals
- SENSIMED Triggerfish®: Promotional Analysis
- Product Overview
- Product Website / Brochure Analysis
- Messages for Healthcare Professionals
- Messages for Patients
- Product User Manual Analysis
- Other Messages
- Other Promotional Activities
- Publication in Journals
- Presence in Conferences
- TECHNOLOGY PROFILES
- Chapter Overview
- Next Generation Contact Lenses: Novel Technologies
- EyePrintPRO™
- Developer Overview
- Technology Overview
- Working Mechanism
- Interscatter Communication Technology
- Developer Overview
- Technology Overview
- Working Mechanism
- Leo Lens Technology
- Developer Overview
- Technology Overview
- Working Mechanism
- Nanowafer Technology
- Developer Overview
- Technology Overview
- Working Mechanism
- The Diamond Eye™ Technology
- Developer Overview
- Technology Overview
- Working Mechanism
- PATENT ANALYSIS
- Chapter Overview
- Scope and Methodology
- Next Generation Contact Lenses and Visual Prostheses: Patent Analysis
- Analysis by Publication Year
- Analysis by Geographical Location
- Analysis by CPC Classification
- Emerging Focus Areas
- Leading Industry Players by Number of Patents
- Leading Non-Industry Players by Number of Patents
7.4. Next Generation Contact Lenses and Visual Prostheses: Patent Benchmarking Analysis (Industry Players)
7.4.1. Analysis by CPC Classification
7.4.2. Analysis by Geography
7.5. Next Generation Contact Lenses and Visual Prostheses: Patent Benchmarking Analysis (Non-Industry Players)
7.5.1. Analysis by CPC Classification
7.5.2. Analysis by Geography
7.6. Next Generation Contact Lenses and Visual Prostheses: Patent Valuation Analysis
- PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Next Generation Contact Lenses and Visual Prostheses: List of Partnerships and Collaborations
8.3.1. Analysis by Type of Partnership
8.3.2. Analysis by Type of Organization
8.3.3. Analysis by Area of Application
8.3.4. Analysis by Target Indication
8.3.5. Regional Analysis
8.3.5.1. Intercontinental and Intracontinental Agreements
- EMERGING TRENDS ON SOCIAL MEDIA
9.1. Chapter Overview
9.2. Next Generation Contact Lenses and Visual Prostheses: Trends on Twitter
9.2.1. Social Media Analysis: Trending Words / Phrases Related to Next Generation Contact Lenses and Visual Prostheses on Twitter
9.2.2. Social Media Analysis: Most Prolific Authors on Twitter
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device CRO Market is anticipated to grow at a CAGR 6.4% by 2030
Roots Analysis has done a detailed study on Medical Device CRO Market (2nd Edition), 2020-2030, covering various important aspects of the industry and identifying key future growth opportunities.
Key Market Insights
- Since 2015, over 7,500 medical device focused clinical trials, involving the participation of close to 2.9 million patients across different hospitals / medical centers, have been registered worldwide
- Over 300 CROs presently claim to possess the necessary capabilities to offer a wide range of preclinical and clinical research-related services to medical device-focused business entities
- The market landscape is highly fragmented, featuring the presence of both established players and new entrants; majority of such firms are located in the developed geographies
- Owing to the high competition in this field, stakeholders are steadily expanding their capabilities in order to augment their respective service portfolios and also comply to evolving industry benchmarks
- Over the years, the domain has witnessed an increase in merger and acquisition activity, with many CROs expanding their presence across multiple geographies and growing their respective service portfolios
- Several companies in this domain have established strong brand positions across different regions; in future, such companies are anticipated to contribute the most to the overall revenue generation potential
- Driven by the growing demand for effective treatment modalities across various therapeutic areas, the market is poised to witness sustained growth across various device classes and geographies
- In the long term, we expect the market to reach over USD 15 billion; the current and future opportunity is likely to be distributed across companies of different sizes offering various types of clinical and preclinical services
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Overview of Medical Devices
- Historical Evolution of Medical Devices
- Classification of Medical Devices
- Overview of Contract Research Organizations (CROs)
- Evolution of CROs
- Role of CROs in the Medical Device Industry
- Types of Medical Device CROs
- Types of Services Offered by CROs
- Advantages of Outsourcing Operations to CROs
- Risks and Challenges Associated with Outsourcing
- Key Considerations for Selecting a Suitable CRO Partner
- MARKET LANDSCAPE
- Chapter Overview
- Medical Device CROs: Clinical Service Providers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Location of Headquarters
- Analysis by Company Size and Location of Headquarters
- Analysis by Area of Specialization
- Analysis by Device Class
- Analysis by Type of Clinical Operation Services Offered
- Analysis by Type of Regulatory Affairs-related Services Offered
- Analysis by Type of Additional Services Offered
- Analysis by Medical Device Regulatory Compliance Authorities
- Medical Device CROs: Preclinical Service Providers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Location of Headquarters
- Analysis by Company Size and Location of Headquarters
- Analysis by Type of Preclinical Services Offered
- Medical Device CROs: Standalone Service Providers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Location of Headquarters
- Analysis by Company Size and Location of Headquarters
- REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
- Chapter Overview
- General Regulatory and Reimbursement Guidelines for Medical Devices
- Regulatory and Reimbursement Landscape in North America
- The US Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Canadian Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Mexican Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Regulatory and Reimbursement Landscape in Europe
- Overall Scenario
- Overall Regulatory Authority
- Overall Review / Approval Process
- The UK Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The French Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The German Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Italian Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Spanish Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
- The Australian Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Brazilian Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Chinese Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Indian Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- The Israeli Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- The Japanese Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The New Zealand Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Singapore Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The South Korean Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The South African Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- The Taiwan Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Payer Mix
- Reimbursement Process
- The Thailand Scenario
- Regulatory Authority
- Review / Approval Process
- Reimbursement Landscape
- Comparison of Regional Regulatory Control
- Concluding Remarks
- The Australian Scenario
- Overall Scenario
- The US Scenario
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device Contract Manufacturing Market is projected to grow at an annualized rate of 8%, till 2030
Roots Analysis has done a detailed study on Medical Device Contract Manufacturing Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- Over 270 companies worldwide have the necessary expertise and authorization to offer contract manufacturing services for various types of medical devices, including therapeutic and diagnostic products
- The market landscape is fragmented, featuring the presence of both established players and new entrants; presently, most medical device manufacturing facilities are located in the developed geographies
- Medical device CMOs are actively engaged in aligning their operations to comply to the standards established by various global and regional regulatory bodies
- Companies involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and comply to evolving industry benchmarks
- In the last six years, over 9,600 trials evaluating various medical devices have been registered by different types of sponsors covering a wide range of therapeutic areas
- Implants have emerged as one of the most prominent segments for which the acquisition activity is relatively higher; key value drivers behind such acquisitions include capability addition and geographical consolidation
- Driven by a rapidly growing demand, medical device contract services market is anticipated to grow at annualized rate of 8% for a variety of therapeutic areas and geographies for finished products
- Established CMOs currently occupy a major share; in the long term, the opportunity is anticipated to be better distributed across different types of companies, device classes and application areas
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Medical Devices: An Overview
- History of Medical Devices
- Classification of Medical Devices
- Medical Device Manufacturing
- Challenges Associated with Medical Device Manufacturing
- Role of CMOs in Medical Device Manufacturing
- Role of Automation in Medical Device Manufacturing Process
- Historical Timeline for Medical Device CMOs
- Services Offered by Medical Device CMOs
- Advantages Offered by Medical Device CMOs
- Risks associated with Outsourcing to CMOs
- Key Considerations
- Concluding Remarks
- REGULATORY LANDSCAPE FOR MEDICAL DEVICES
- Chapter Overview
- General Regulatory Guidelines for Medical Devices
- Regulatory Landscape in North America
- The US Scenario
- Regulatory Authority
- Review / Approval Process
- The Canadian Scenario
- Regulatory Authority
- Review / Approval Process
- Regulatory Landscape in Europe
- Overall Scenario
- Regulatory Authority
- Review / Approval Process
- Case Study: Brexit -The UK Scenario
- Overall Scenario
- Regulatory Landscape in Asia-Pacific
- The Chinese Scenario
- Regulatory Authority
- Review / Approval Process
- The Japanese Scenario
- Regulatory Authority
- Review / Approval Process
- The Australian Scenario
- Regulatory Authority
- Review / Approval Process
- Comparison of Regional Regulatory Environment
- The Chinese Scenario
- The US Scenario
- MARKET OVERVIEW: THERAPEUTIC DEVICES
- Chapter Overview
- Medical Device CMOs Offering Services for Therapeutic Devices
- Analysis by Year of Establishment
- Analysis by Size of Employee Base
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facility
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Production Services Offered
- Analysis by Post-production Services Offered
- Analysis by Other Services Offered
- Analysis by Device Class
- Analysis by Type of Material(s) Handled
- Analysis by Scale of Operation
- Leading Players
- MARKET OVERVIEW: DIAGNOSTIC DEVICES
- Chapter Overview
- Medical Device CMOs Offering Services for Diagnostic Devices
- Analysis by Year of Establishment
- Analysis by Size of Employee Base
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facility
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Production Services Offered
- Analysis by Post-Production Services Offered
- Analysis by Other Services Offered
- Analysis by Device Class
- Analysis by Type of Material(s) Handled
- Analysis by Scale of Operation
- Leading Players
- MARKET OVERVIEW: DELIVERY SYSTEMS AND OTHERS
- Chapter Overview
- Catheters
- Medical Device CMOs Offering Services for Catheters
- Analysis by Year of Establishment
- Analysis by Size of Employee Base
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facility
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Production Services Offered
- Analysis by Post-Production Services Offered
- Analysis by Other Services Offered
- Analysis by Device Class
- Analysis by Type of Material(s) Handled
- Analysis by Scale of Operation
- Leading Players
- Drug Delivery Devices
- Medical Device CMOs Offering Services for Drug Delivery Devices
- Analysis by Year of Establishment
- Analysis by Size of Employee Base
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facility
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Production Services Offered
- Analysis by Post-Production Services Offered
- Analysis by Other Services Offered
- Analysis by Device Class
- Analysis by Type of Material(s) Handled
- Analysis by Scale of Operation
- Leading Players
- Other Devices
- Medical Device CMOs Offering Services for Other Medical Devices
- Analysis by Year of Establishment
- Analysis by Size of Employee Base
- Analysis by Location of Headquarters
- Analysis by Location of Manufacturing Facility
- Analysis by Regulatory Certifications / Accreditations
- Analysis by Production Services Offered
- Analysis by Post-Production Services Offered
- Analysis by Other Services Offered
- Analysis by Device Class
- Analysis by Type of Material(s) Handled
- Analysis by Scale of Operation
- BENCHMARK ANALYSIS
- Chapter Overview
- Benchmark Analysis: Methodology
- Region-wise Benchmark Analysis
- North America, Peer Group I
- North America, Peer Group II
- North America, Peer Group III
- North America, Peer Group IV
- North America, Peer Group V
- North America, Peer Group VI
- North America, Peer Group VII
- Europe, Peer Group VIII
- Europe, Peer Group IX
- Europe, Peer Group X
- Asia, Peer Group XI
- Asia, Peer Group XII
- Concluding Remarks
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Autoinjectors Market Worth USD 2.5 billion by 2030 | Roots Analysis
Roots Analysis has done a detailed study on Global Autoinjectors Market (3rd Edition), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
Key Market Insights
- Currently, several companies claim to be engaged in the development / manufacturing of various types of autoinjectors, most of which are disposable systems that use prefilled syringes as primary drug containers
- About 90 autoinjector-based combination products have been approved for the treatment of a variety of clinical conditions; the subcutaneous route being the preferred mode of drug delivery via such devices
- In order to gain a competitive edge in the market, many autoinjector manufacturers are focusing on the integration of advanced features into their respective products and affiliated offerings
- Over time, more than 4,600 patents have been filed / granted related to autoinjectors and affiliated products; most of the new intellectual property is related to additional features, such as safety locks and device connectivity
- Eminent scientists from renowned organizations and academic institutions across the world have made valuable contributions to this field, in terms of leading clinical research efforts and developing novel technologies
- Several autoinjector developers have established strong brand positions in different geographies; the focus, in the near term, is likely to be on further enhancing device features for better disease management and improved patient compliance
- An evaluation of 200+ marketed and pipeline products revealed that a variety of drugs / product candidates are likely to be considered for administration via autoinjectors in the near future
- Case Study: Owing to the complexities associated with the manufacturing and assembly of autoinjector drug delivery systems, industry players are known to frequently engage the services of contract service providers
- Currently, disposable autoinjector products for small molecule drugs dominate the market; however, in the foreseen future, the demand for reusable devices is anticipated to witness significant growth
- Given the recent approvals and presence of multiple drug candidates in later stages of development, the market opportunity is likely to be distributed across different therapeutic areas, routes of administration and geographies
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Types of Drug Delivery Systems
- Drawbacks of Conventional Parenteral Delivery Systems
- Needlestick Injuries
- Incidence and Cost Burden
- Government Legislation for the Prevention of Needlestick Injuries
- Emerging Trend of Self-Administration
- Rising Burden of Chronic Diseases
- Healthcare Cost Savings
- Need for Immediate Treatment in Emergency Situations
- Growth of Injectable Biologics Market
- Addressing Key User Safety Requirements
- Types of Self- Administration Devices
- Prefilled Syringes
- Pen-Injectors
- Needle-Free Injectors
- Autoinjectors
- Large Volume Wearable Injectors
- Overview of Autoinjectors
- Components of Autoinjectors
- Classification of Autoinjectors
- On the Basis of Mechanism of Action
- On the Basis of Usability
- On the Basis of Type of Dose
- Manufacturing / Packaging of Autoinjectors
- Benefits of Autoinjectors
- Regulatory Considerations
- Medical Devices
- Drug Device Combination Products
- Future Perspectives
- PRIMARY DRUG CONTAINERS
- Chapter Overview
- Types of Packaging
- Introduction to Primary Drug Containers
- Role of Primary Drug Containers
- Types of Primary Drug Containers
- Cartridges
- Components of Cartridges
- Types of Cartridges
- Single Chamber Cartridge
- Dual Chamber Cartridge
- Cartridges Available in the Market
- Syringes
- Components
- Types of Syringes
- Based on Number of Chambers
- Based on Type of Needle
- Prefilled Syringe Systems Available in the Market
- Glass Prefilled Syringes
- Plastic Prefilled Syringes
- Vials
- Components
- Vials Available in the Market
- Comparison of Fabrication Materials
- Cartridges
- AUTOINJECTORS: CURRENT MARKET LANDSCAPE
- Chapter Overview
- Autoinjectors: List of Devices
- Analysis by Usability
- Analysis by Type of Primary Container
- Autoinjectors: List of Additional Parameters of Devices
- Analysis by Volume of Container
- Analysis by Type of Dose
- Analysis by Route of Administration
- Analysis by Actuation Mechanism
- Analysis by Type of Feedback Mechanism
- Autoinjectors: List of Developers
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Geographical Location of Headquarters
- PRODUCT COMPETITIVENESS ANALYSIS
- Chapter Overview
- Methodology
- Assumptions and Key Parameters
- Product Competitiveness Analysis
- Disposable Autoinjectors
- Reusable Autoinjectors
- BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1 Chapter Overview
7.2. Scope and Methodology
7.3. Brand Positioning Matrix: Antares Pharma
7.4. Brand Positioning Matrix: BD
7.5. Brand Positioning Matrix: DALI Medical Devices
7.6. Brand Positioning Matrix: Elcam Drug Delivery Devices
7.7. Brand Positioning Matrix: Oval Medical Technologies
7.8 Brand Positioning Matrix: Owen Mumford
7.9. Brand Positioning Matrix: SHL Medical
7.10 Brand Positioning Matrix: Union Medico
7.11. Brand Positioning Matrix: Ypsomed
- PATENT ANALYSIS
- Chapter Overview
- Scope and Methodology
- Autoinjectors: Patent Analysis
- Analysis by Application Year
- Analysis by Issuing Authority
- Analysis by CPC Symbols
- Emerging Areas
- Leading Players Based on Number of Patents
- Autoinjectors: Patent Benchmarking Analysis
- Analysis by Patent Characteristics
- Analysis by Geography
- Autoinjectors: Patent Valuation Analysis
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/autoinjectors-market/293.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Antibody Drug Conjugates Market Headed for Growth and Global Expansion by 2030
Key Market Insights
- Eminent representatives from different biopharmaceutical companies confirm the sustained interest in ADC therapeutics, highlighting the technological innovation that is driving contemporary R&D initiatives
- Presently, over 240 ADC therapy candidates are being evaluated in clinical / preclinical stages for treating a variety of solid tumors / hematologic cancers
- The pipeline features product candidates that target a wide range of biological antigens and are equipped with different cytotoxic warheads; a number of companies are focused on developing novel drug conjugates
- In order to gain a competitive edge in the market, ADC developers are actively exploring new biological targets, conducting clinical trials across different geographies to treat diverse disease indications
- A number of eminent scientists from renowned universities, owing to their involvement in clinical development efforts, have emerged as key opinion leaders within this market
- Over the years, more than 16,000 patents related to ADCs have been filed / granted across the world, indicative of the ongoing pace of R&D activity in this field of research
- Several investors, having realized the opportunity within this upcoming segment of targeted cancer therapeutics industry, have invested over USD 5 billion, in the period between 2011 and 2019
- The increasing interest in this field is also reflected in the partnership activity; deals inked in the recent past were mostly focused on licensing of products / technologies, involving both international and indigenous stakeholders
- In the recent years, several developer companies have initiated clinical trials to evaluate the therapeutic potential of ADCs in combination with other drug / therapy classes
- Anticipating the launch of several product candidates, stakeholders are exploring diverse commercialization strategies across different stages of the launch cycle along with the appropriate reimbursement strategies
- Given the complexities associated with the development and production of ADCs, CMOs are indispensable to the R&D and manufacturing activity in this domain; some CMOs have even pioneered the novel ADC technology platforms
- Case Study: In order to keep patients and healthcare professionals informed and aware of the developments, companies are deploying diverse promotional strategies for their respective products
- With a promising development pipeline and encouraging clinical results, the global market is anticipated to witness growth at an annualized rate of over 20% during the next decade
- The anticipated future opportunity is likely to be distributed across different types of linkers and target antigens as more late-stage drugs get commercialized and existing marketing authorizations are expanded
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Table of Contents
- PREFACE
- Scope of the Report
- Research Methodology
- Chapter Outlines
- EXECUTIVE SUMMARY
- INTRODUCTION
- Chapter Overview
- Evolution of Anticancer Therapy
- Cancer Treatment Methods
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapies
- Monoclonal Antibody-Based Anticancer Therapies
- Components of Antibody Drug Conjugates (ADCs)
- Antibody
- Cytotoxin
- Linker
- Advantages of ADC Therapeutics over Traditional Therapeutic Interventions
- Differences Between Small Molecule Drugs, Monoclonal Antibody Therapies and ADCs
- Pharmacokinetic Properties of ADCs
- Absorption
- Distribution
- Metabolism and Excretion
- MARKET OVERVIEW
- Chapter Overview
- ADC Therapeutics: Clinical Pipeline
- Analysis by Phase of Development
- Analysis by Indication
- Analysis by Line of Treatment
- Analysis by Dosing Regimen
- Analysis by Type of Therapy
- Analysis by Target Antigen
- Analysis by Antibody Origin
- Analysis by Antibody Isotype
- Analysis by Type of Linker
- Analysis by Type of Payload / Warhead
- Key Technology Providers
- Discontinued Drugs
- ADC Therapeutics: Preclinical Pipeline
- Analysis by Phase of Development
- Analysis by Indication
- Analysis by Target Antigen
- Key Players: Analysis by Number of ADC Therapeutics
- ADC Therapeutics: Developer Landscape
- Analysis by Year of Establishment
- Analysis by Company Size
- Analysis by Geographical Location
- Logo Landscape: Analysis by Size and Target Indication
- Novel Drug Conjugates
- COMPANY AND DRUG PROFILES
- Chapter Overview
- AbbVie
- Company Overview
- Financial Information
- Pipeline Overview
- Rovalpituzumab Tesirine / ROVA-T
5.2.3.1.1 Drug Overview
5.2.3.1.2. Mechanism of Action
5.2.3.1.3. Clinical Development Status
5.2.3.1.4. Key Clinical Trial Results
- Teliso-V / Telisotuzumab Vedotin / ABBV-399
5.2.3.2.1 Drug Overview
5.2.3.2.2. Mechanism of Action
5.2.3.2.3. Clinical Development Status
5.2.3.2.4. Key Clinical Trial Results
- Recent Developments and Future Outlook
- Astellas Pharma
- Company Overview
- Financial Information
- Pipeline Overview
- Enfortumab Vedotin
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- ASG16-M8F
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- Enfortumab Vedotin
- AstraZeneca
54.1. Company Overview
5.4.2. Financial Information
5.4.3. Pipeline Overview
5.4.3.1. LUMOXITI™
5.4.3.1.1. Drug Overview
5.4.3.1.2. Mechanism of Action
5.4.3.1.3. Clinical Development Status
5.4.3.1.4. Key Clinical Trial Results
5.4.4. Recent Developments and Future Outlook
- Daiichi Sankyo
- Company Overview
- Financial Information
- Pipeline Overview
- Trastuzumab deruxtecan / DS-8201a / DS 8201
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- Trastuzumab deruxtecan / DS-8201a / DS 8201
- ImmunoGen
- Company Overview
- Financial Information
- Pipeline Overview
- IMGN853 / Mirvetuximab soravtansine
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- IMGN853 / Mirvetuximab soravtansine
- Immunomedics
- Company Overview
- Financial Information
- Pipeline Overview
- IMMU-130
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- IMMU-130
- Pfizer
- Company Overview
- Financial Information
- Pipeline Overview
- CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- MYLOTARG™ / Gemtuzumab Ozogamicin
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- CMC-544 / BESPONSA® / Inotuzumab Ozogamicin
- Roche / Genentech
- Company Overview
- Financial Information
- Pipeline Overview
- KADCYLA®
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- RG-7596
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- KADCYLA®
- Seattle Genetics
- Company Overview
- Financial Information
- Pipeline Overview
- ADCETRIS®
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- SGN- LIV1A
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- ADCETRIS®
- Synthon
- Company Overview
- Financial Information
- Pipeline Overview
- SYD985 / Trastuzumab Duocarmazine
- Drug Overview
- Mechanism of Action
- Clinical Development Status
- Key Clinical Trial Results
- Recent Developments and Future Outlook
- SYD985 / Trastuzumab Duocarmazine
- Other Companies
- Bayer HealthCare
- Company Overview
- Financial Information
- Pipeline Overview
- Recent Developments and Future Outlook
- Biotest Pharmaceuticals
- Company Overview
- Financial Information
- Pipeline Overview
- Recent Developments and Future Outlook
- Bayer HealthCare
- KEY THERAPEUTIC AREAS
- Chapter Overview
- Hematological Malignancies
- Leukemias and Lymphomas
- Leukemia: Introduction and Epidemiology
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Lymphoma: Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Leukemia / Lymphoma
- Leukemia: Introduction and Epidemiology
- Multiple Myeloma
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Multiple Myeloma
- Solid Tumors
- Lung Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Lung Cancer
- Breast Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Breast Cancer
- Ovarian Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Ovarian Cancer
- Bladder Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Bladder Cancer
- Colorectal Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Colorectal Cancer
- Prostate Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Prostate Cancer
- Gastric Cancer
- Introduction and Epidemiology
- Current Treatment Landscape
- ADC Therapeutics for Prostate Cancer
- Lung Cancer
- Leukemias and Lymphomas
- KEY OPINION LEADERS
- Chapter Overview
- Methodology
- Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
- Geographical Distribution of Key Opinion Leaders
- Experts on ADCETRIS®
- Experts on KADCYLA®
- Experts on MYLOTARG™
- Experts on Other ADCs
- Prominent Key Opinion Leaders (KOLs)
- KOL Benchmarking: Roots Analysis versus Third Party Scoring (ResearchGate Score)
- Most Active Key Opinion Leaders
- Profile: KOL A (Celgene)
- Profile: KOL B (Western Regional Medical Center)
- Profile: KOL C (MedStar Washington Hospital Center)
- Profile: KOL D (Cancer Institute and Hospital)
- Profile: KOL E (Comprehensive Cancer Centers of Nevada)
- Profile: KOL F (Hopital Tenon)
- Profile: KOL G (Cleveland Clinic)
- Geographical Distribution of Key Opinion Leaders
- TARGET COMPETITIVENESS ANALYSIS
- Chapter Overview
- Scope and Methodology
- Competitiveness Analysis: Key Clinical Targets for ADCs
- Four-Dimensional Bubble Analysis
8.3.2 Five-Dimensional Spider Web Analysis
- Competitiveness Analysis: Key Preclinical Targets for ADCs
- Two-Dimensional Scatter Plot Analysis
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Next Generation Contact Lenses and Visual Prostheses Market Worth USD 3.7 billion by 2030 | Roots Analysis
Recent technological advances in the field of ophthalmology and the availability of new biomaterials have substantially expanded the range of potential application areas of contact lenses and enabled the development of novel prosthetic products
Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Contact Lenses and Visual Prostheses Market, 2019-2030.”
The report features an extensive study of the current market landscape of therapeutic contact lenses, drug-eluting contact lenses, diagnostic / monitoring contact lenses and visual prostheses. The study lays emphasis on the novel products and technologies that are being developed for the treatment of ocular disorders, which generally cause severe visual impairment or blindness. In addition to other elements, the study includes:
- A detailed review of the landscape of novel ophthalmic products, highlighting the different categories of contact lenses and visual prostheses (bionic eye technologies) developed / being developed by various players across the world.
- An analysis of the key promotional strategies that have been adopted by the developers of marketed products.
- Brief profiles of the novel technologies that are being developed to expand the functionality of contact lenses.
- An in-depth analysis of the various patents granted / filed related to next generation contact lenses and visual prostheses since 2013.
- An analysis of the partnerships that have been established in this domain.
- A study of prevalent and emerging trends, and the popularity of next generation contact lenses and visual prostheses, as observed on the social media platform, Twitter.
- A list of key opinion leaders (KOLs) in this domain, featuring a 2X2 analysis to assess the relative experience of certain individuals., who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of Product
- Contact Lenses
- Visual Prostheses
Type of Lenses
- Therapeutic Contact Lenses
- Drug-eluting Contact Lenses
- Diagnostics and Monitoring Contact Lenses
Target Indication
- Age-related Macular Degeneration
- Aniridia
- Diabetes
- Glaucoma
- Retinitis Pigmentosa
Key Geographical Region
- North America
- EU5
- Asia-Pacific
Target Therapeutic Area
- CNS disorders
- Cardiovascular disorders
- Oncological disorders
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
- Michal Shavit (Head of Sales and Marketing, EyeYon Medical)
- Mark E. Byrne (Co-Founder and Chief Technical Officer, OcuMedic)
- Praful Doshi (Founder, Chief Executive Officer and Chief Technical Officer, Leo Lens Technology)
Key companies covered in the report
- EyePrint Prosthetics
- University of Washington
- Leo Lens Technology
- Baylor College of Medicine
- iBIONICS
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Medical Device CRO Market is estimated to be worth over USD 15.7 billion by 2030
Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs
Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.
The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices. The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe. In addition to other elements, the study includes:
- A detailed review of the overall landscape of medical device CROs.
- An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, and Asia-Pacific and rest of the world.
- Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices.
- An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domain
- A competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.
- A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio).
- A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices.
- A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.
- A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.
- An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Phase of Development
- Clinical
- Preclinical
Types of Preclinical Services Offered
- Biocompatibility testing
- Sterility and microbiology testing
- Material characterization and analytical services
- Others
Types of Clinical Services Offered
- Clinical trial management
- Data management
- Regulatory affairs management
- Consulting
- Others
Device Class
- Class I medical devices
- Class II medical devices
- Class III medical devices
Target Therapeutic Area
- CNS disorders
- Cardiovascular disorders
- Oncological disorders
- Bone disorders
- Respiratory disorders
- Pain management disorders
- Ophthalmic disorders
- Psychological disorders
- Metabolic disorders
- Others
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies
- Lajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)
- Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)
- Christian Wolflehner (General Manager, CW Research & Management)
- Troy Mccall (Chief Operating Officer, CROMSOURCE)
- Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)
- Omprakash (Technical Director and Partner, Vyomus Consulting)
- Tania Persson (Director of Business Development, A+ Science)
- Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO)
Key companies covered in the report
- Avania (formerly known as Factory CRO)
- Charles River Laboratories
- Clinlogix
- CROMSOURCE
- CSSi LifeSciences™
- Eurofins Medical Device Testing
- genae
- IMARC Research
- IQVIA
- Medpace
- NAMSA
- Qserve Group
- Regulatory and Clinical Research Institute (now a part of Covance)
- WuXi AppTec
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Synthesis, Modification and Purification Services Market Report – Industry Size, Share, Trends, Growth and Forecast Till 2030
According to experts, the use of oligonucleotides as a treatment option is limited due to complexities associated with the synthesis of such compounds. Similar to small molecule drugs, oligonucleotides can be manufactured via chemical synthesis methods, solid phase synthesis being one of the most popular approaches used.
Key Inclusions
- A detailed review of the current status of the market with respect to oligonucleotide manufacturers focused on research and diagnostic, and therapeutic applications. It features information on the year of establishment, company size, scale of operation (preclinical, clinical, and commercial), location of headquarters, number of manufacturing facilities, along with their locations (country-wise), and regulatory accreditations and certifications received by them, type of oligonucleotide manufactured (antisense oligonucleotides, aptamers, decoys, miRNA, shRNA, siRNA, specialty amidites, and others), type of offering (custom synthesis, modification and purification), type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, sequencing capabilities, stability studies, quality assurance and control, scale-up, fill/finish, downstream processing, regulatory support, data analytics and reporting, and others), type of modification(s) offered (amino modifiers, backbone modifications, fluorescent probes, dyes and quenchers, modified bases, phosphorylation, thiol modifications, and others), type of purification method(s) used (desalting, cartridge purification, HPLC, ion exchange purification, PAGE, and others), and compliance to cGMP standards.
- A company competitiveness analysis, highlighting prominent oligonucleotide manufacturers for research and diagnostic, and therapeutic applications, based on supplier strength (which was calculated by considering the size of employee base of a company and its experience in this field) and service strength (quantified based on scale of operation, expertise in manufacturing different types of oligonucleotides, type of offering, type of manufacturing service(s) offered, type of modification(s) offered, type of purification method(s) used, compliance to cGMP standards, as well as number and location of manufacturing facilities).
- Elaborate profiles of key players that offer a diverse range of capabilities for custom synthesis, modification and purification of oligonucleotides for use in research and diagnostic, and therapeutic applications. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, details on partnerships, recent developments (expansions), and awards received by the firm, as well as an informed future outlook.
- An analysis of the various partnerships pertaining to oligonucleotide manufacturing, which have been established since 2014, based on several parameters, such as the year of partnership, type of partnership, type of partner, most active players (in terms of number of partnerships signed), and a geographical analysis.
- An analysis of the various expansion initiatives undertaken by service providers engaged in this domain, in order to augment their respective oligonucleotide manufacturing capabilities, over the period 2014-2019, taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation (preclinical, clinical and commercial), application (research and manufacturing operations), and location of manufacturing facility.
- A detailed analysis of completed, ongoing and planned clinical research studies of various oligonucleotide-based drug products, highlighting prevalent trends across several relevant parameters, such as trial registration year, phase of development, type of oligonucleotide, current trial recruitment status, study focus area, key therapeutic areas (in terms of number of trials undertaken / conducted), enrolled patient population and trial location, and leading industry and non-industry players (in terms of number of trials undertaken / conducted).
- An estimate of the overall, annual capacity for manufacturing oligonucleotides based on data reported by industry stakeholders in the public domain; it highlights the distribution of available oligonucleotide synthesis capacity on the basis of company size (small, mid-sized, and large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
- An informed estimate of the annual commercial demand for oligonucleotide-based drug products (in kilograms), taking into account the marketed oligonucleotide products; the analysis takes into consideration the target patient population, dosing frequency and dose strength, of the aforementioned products. The annual clinical demand for oligonucleotide-based drug products was also estimated, taking into account ongoing and planned clinical trials.
- A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing custom synthesis, modification and purification services for oligonucleotides.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of Manufacturing
- Custom Manufacturing
- Large-scale Manufacturing
Type of Oligonucleotides Manufactured
- Antisense Oligonucleotides
- miRNAs
- shRNAs
- siRNAs
- Other Oligonucleotides
Scale of Operation
- Clinical
- Commercial
Purpose of Production
- In-house
- Outsourced
Target Therapeutic Area
- Autoimmune Disorders
- Cardiovascular Disorders
- Genetic Disorders
- Infectious Diseases
- Metabolic Disorders
- Neuromuscular Disorders
- Oncological Disorders
- Ophthalmic Disorders
- Other Therapeutic Areas
Size of manufacturer
- Small
- Mid-sized
- Large
Key Geographical Region
- North America
- Europe
- Asia-Pacific and Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies
- Joachim Bertram (Chief Scientific Officer and Managing Director, IBA Lifesciences)
- Tobias Pohlmann (Founder and Managing Director, BianoScience)
Key Questions Answered
- Who are the leading manufacturers of oligonucleotides for use in research, diagnostic and therapeutic applications?
- What are the preferred custom synthesis, modification and purification methods used for oligonucleotides?
- What are the key challenges faced by oligonucleotide manufacturers?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the recent expansion initiatives undertaken by service providers within this domain?
- What is the annual clinical and commercial demand for oligonucleotides?
- What is the current, installed manufacturing capacity for oligonucleotides?
- What percentage of oligonucleotide manufacturing operations are outsourced to service providers?
- What are the opportunities in emerging markets for oligonucleotide manufacturing?
- How is the current and future market opportunity likely to be distributed across key market segments?
- What are the anticipated future trends related to oligonucleotide manufacturing?
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Neoantigen Targeted Therapies Market Analysis and Forecast to 2030
Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The World Health Organization has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Conventional treatment options, such as chemotherapy, surgery and radiation therapy, continue to demonstrate limited efficacy in late-stage cancers.
Get Detailed Analysis of Neoantigen Targeted Therapies Market Research Reports
Key Inclusions
• A detailed assessment of the current market landscape, providing information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of treatment (personalized and off-the-shelf), type of therapy (monotherapy and combination therapy), type of immunotherapy, target indication, line of treatment, and route of administration of the drugs / therapies that are being developed for the treatment of cancer.
• Detailed profiles of developers of neoantigen targeted therapies (shortlisted on the basis of the number of pipeline products), featuring an overview of the company, its financial information (if available), a detailed description of its product portfolio and recent collaborations. In addition, each profile includes an informed future outlook.
• A detailed publication analysis of close to 300 peer-reviewed, scientific articles published during the period 2015-2019 (till February), highlighting the research focus within the industry. It also highlights the key trends observed across the publications, including information on target disease indications, affiliated cancer immunotherapies, and analysis based on various relevant parameters, such as study type (review article, research article and meta-analysis), year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.
• An in-depth analysis of the various patents that have been filed / granted related to neoantigens till April 2019. It includes information on key parameters, such as patent type, publication year, issuing authority, assigned CPC symbol, emerging focus areas and leading industry / academic players (in terms of size of intellectual property portfolio).
• An analysis of the various partnerships pertaining to neoantigen targeting therapies, which have been established till March 2019, based on various parameters, such as the type of partnership, year of partnership, target disease indications, type of immunotherapy and the most active players.
• An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are focused on developing neoantigen targeted therapies.
• Informed estimates of the existing market size and the future opportunity for neoantigen targeted therapies, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of neoantigen targeted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period 2019-2030.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Key Drug Discovery Steps
Type of target disease indication
• Bone cancer
• Colorectal cancer
• Gynecological cancer
• Non-small cell lung cancer
• Renal cell carcinoma
• Other cancers
Type of neoantigens
• Personalized neoantigens
• Off-the-shelf neoantigens
Type of immunotherapy
• Dendritic cell vaccines
• DNA / RNA-based vaccines
• Protein / peptide-based vaccines
• TIL-based therapies
Route of administration
• Intradermal
• Intravenous
• Subcutaneous
• Other routes
Key geographical regions
• North America
• Europe
• Rest of the World
The report also features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes. The report includes detailed transcripts of discussions held with the following experts:
• Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
• Ella Sorani (Vice President Research and Development, BioLineRx)
• Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
Key Questions Answered
• What are the prevalent trends related to R&D activity focused on neoantigen based therapies?
• What are the clinical conditions for which neoantigen targeted therapies are being developed?
• What are the key challenges faced by neoantigen-based therapy developed?
• Who are the leading industry and non-industry players?
• What are the key factors that are likely to influence the evolution of the neoantigen targeted therapies market?
• What are the reasons for partnership activity among stakeholders in this industry?
• Who are the key investors in neoantigen targeted therapies?
• What is share of neoantigen targeted therapies in the immunotherapy market?
• How is the current and future market opportunity likely to be distributed across key market segments and geographies?
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/neoantigen-targeted-therapies-market-2019-2030/257.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Computer-Aided Drug Discovery Services Market Report – Industry Size, Share, Trends, Growth and Forecast Till 2030
The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion.
Get Detailed Analysis of In Silico / Computer-Aided Drug Discovery Services Market Research Reports
Key Inclusions
• A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
• Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
• Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
• A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
• An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
• A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
• A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
• An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
• A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
• Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
• A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
• A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Key Drug Discovery Steps
• Target Identification
• Target Validation
• Hit Generation
• Hit-to-Lead
• Lead Optimization
Type of Large Molecule
• Antibodies
• Proteins
• Peptides
• Nucleic Acids
• Vectors
Company Size
• Small
• Mid-sized
• Large
Target therapeutic Area
• Autoimmune Disorders
• Blood Disorders
• Cardiovascular Disorders
• Gastrointestinal and Digestive Disorders
• Hormonal Disorders
• Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
• Infectious Diseases
• Metabolic Disorders
• Mental Disorders
• Musculoskeletal Disorders
• Neurological Disorders
• Oncological Disorders
• Respiratory Disorders
• Skin Disorders
• Urogenital Disorders
• Others
Type of Sponsor
• Industry Players
• Non-Industry Players
Key Geographical Regions
• North America
• Europe
• Asia-Pacific
The report includes detailed transcripts of discussions held with the following experts:
• John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
• Sven Benson (Founder, candidum)
• Mark Whittaker (Senior Vice President, Evotec)
• Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)
Key Questions Answered
• Who are the leading in silico service providers for discovery of different types of large molecule drugs?
• What are the key challenges associated with the discovery of large molecule drugs?
• What is the likely cost saving opportunity associated with the use of in silico tools?
• What are the key computational approaches being used by in silico service providers for drug discovery operations?
• What are the popular business strategies being used by in silico drug discovery service providers?
• How is the current and future market opportunity likely to be distributed across key market segments?
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Human Microbiome Market Research Report 2019-2030
Over time, the efforts of industry stakeholders and clinical researchers in this domain have led to the discovery of novel therapeutic strategies, including the establishment of a gut-brain axis, involving the human microbiome.
Key Inclusions
• A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.
• Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.
• A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.
• A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
• A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
• An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
• An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.
• An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
• An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
• An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.
• An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.
• An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.
The USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:
Type of Therapy (Tx)
• Prescription Drug
• Prebiotics
• Probiotics
Type of Molecule (Tx)
• Small Molecules
• Biologics
Target Indication (Tx+Dx)
• Acne Vulgaris
• Atopic Dermatitis
• Clostridium difficile Infection
• Colorectal Cancer
• Crohn’s Disease
• Diabetes
• Irritable Bowel Syndrome
• Lactose Intolerance
• Lung Cancer
• Nonalcoholic steatohepatitis (NASH)
• Obesity
• Ulcerative colitis
Therapeutic Area (Tx+Dx)
• Autoimmune Disorders
• Dental Disorders
• Digestive and Gastrointestinal Disorders
• Dermatological Disorders
• Infectious Disease
• Metabolic Disorders
• Oncology
• Others
Key Geographical Regions (Tx+Dx)
• North America
• Europe
• Asia-Pacific and Rest of the World
Key Questions Answered
• Who are the leading developers of microbiome therapeutics and diagnostic tests?
• What are the key technology platforms (available / under development) for microbiome-related therapies and diagnostics?
• What are the disease indications against which microbiome-based therapeutics are being evaluated?
• Which companies are targeting gut-brain axis for the development of microbiome therapies?
• Who are the leading (industry and non-industry) players involved in the development of FMT products?
• Who are the key contract research / manufacturing service providers in this domain?
• What is the trend in capital investments in microbiome-related R&D?
• What are the contributions of big pharma players in this domain?
• Which are the popular players offering big data-related services / tools to support microbiome research?
• How is the current and future market opportunity for microbiome-based therapeutics and diagnostics is likely to be distributed across key market segments?
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
Ophthalmic Drugs Contract Manufacturing Market Research Report 2019-2030
Ophthalmic diseases, such as age-related macular degeneration, cataract, diabetic retinopathy, dry eye and glaucoma, are considered among the leading causes of vision loss across the globe.
Key Inclusions
- A detailed review of the ophthalmic drugs contract manufacturing market landscape, featuring a list of over 240 CMOs and analysis based on a number of relevant parameters, such as year of establishment, company size, geographical location, scale of operation (preclinical, pilot, clinical, and commercial), type of product (APIs and FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and injectables), type of primary packaging (ampoules / vials, glass / plastic bottles, ointment tubes, sachets / pouches, blister packing, and other forms), type of service(s) offered (pre-formulation, drug formulation, method validation, process development, analytical testing, stability studies, technology transfer, scale-up, fill / finish, and regulatory support), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
- A company competitiveness analysis, highlighting prominent ophthalmic drug contract manufacturers based on supplier strength (which was calculated considering the size of employee base of a company and its experience in this field) and service strength (quantified based on type of FDF manufactured, type of primary packaging, type of service(s) offered, scale of operation, number and location of manufacturing facilities, and number of regulatory accreditations / certifications)..
- Elaborate profiles of key players based in North America, Europe and Asia-Pacific that offer a diverse range of capabilities for the development, manufacturing and packaging of ophthalmic drug products. Each profile includes an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), and awards and accolades received, as well as an informed future outlook.
- A detailed clinical trial analysis of completed, ongoing and planned studies of various ophthalmic drug products, highlighting prevalent trends across parameters, such as current trial status, trial registration year, enrolled patient population and trial location, phase of development, study design, leading industry and non-industry players (in terms of number of trials undertaken / conducted), study focus, and key disease indications (in terms of number of trials undertaken / conducted).
- An informed estimate of the annual commercial demand for ophthalmic APIs and drug FDFs (in million litres), taking into account the top 30 small molecule-based ophthalmic drugs; the analysis takes into consideration the target patient population, dosing frequency and dose strength of the aforementioned products. The annual clinical demand for ophthalmic drug products was also estimated, taking into account ongoing and planned clinical trials.
- A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market, based on data gathered via secondary and primary research. It also provides the likely distribution of the global ophthalmic product-related manufacturing capacity available across different types of companies (small-sized, mid-sized, and large-sized), scales of operation (preclinical, clinical and commercial), types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and ointment tubes), and key geographical regions (North America, Europe, and Asia-Pacific).
- A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.
- A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to ophthalmic drug developers.
- A discussion on the emerging trends and potential market drivers, such as the growing ophthalmic drugs / therapies pipeline, rise in outsourcing activity for sterile manufacturing operations, adoption of innovative technologies and increasing opportunities in the Asia-Pacific region, which are likely to impact the evolution of the market in the coming years.
- A detailed list of over 55 ophthalmic medical device contract manufacturers, along with information on year of establishment, company size, geographical location, key application area(s) (diagnostics, drug delivery, therapeutics, and others), type of manufacturing service(s) offered (design, component manufacturing, assembly, prototype development, sterilization, quality assurance, and packaging), type of additional service(s) offered (consultancy, documentation, inspection / testing, labelling, logistics, project management, regulatory support, repair, warehouse / storage, and others), scale of operation (pilot and commercial), device class-related expertise (class I, class II and class III), number of manufacturing facilities, their specific locations (country-wise), as well as their regulatory accreditations and certifications.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
Type of product
- Ophthalmic API
- Ophthalmic drug FDF
Type of FDF manufactured
- Solid
- Semi-solid
- Liquid / suspension
Type of primary packaging
- Ampoule / vial
- Glass / plastic bottle
- Ointment tube
- Blister packing
- Other forms
Scale of manufacturing
- Clinical
- Commercial
Company size
- Small
- Mid-sized
- Large
- Very large
Target disease indication
- Age-related macular degeneration
- Dry eye
- Glaucoma
- Other disease segments
Key geographical regions
- North America (US, Canada and Mexico)
- Europe (UK, Germany, France, Spain, Italy and rest of Europe)
- Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
- Rest of the world
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Oligonucleotide Synthesis, Modification And Purification Services Market, Forecast to 2030
Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise in demand, oligonucleotide manufacturers are increasingly consolidating their portfolios, building new capabilities and expanding their respective capacities, mostly through acquisitions, in order to gain a competitive edge.
The USD 5.8 billion (by 2030) financial opportunity within the Oligonucleotide Synthesis, Modification And Purification Services Market has been analysed across the following segments:
Type of manufacturing
- Custom manufacturing
- Large-scale manufacturing
Type of Oligonucleotides manufactured
- Antisense Oligonucleotides
- miRNAs
- shRNAs
- siRNAs
- Other Oligonucleotides
Scale of operation
- Clinical
- Commercial
Purpose of production
- In-house
- Outsourced
Target therapeutic area
- Autoimmune Disorders
- Cardiovascular Disorders
- Genetic Disorders
- Infectious Diseases
- Metabolic Disorders
- Neuromuscular Disorders
- Oncological Disorders
- Ophthalmic Disorders
- Other Therapeutic Areas
Size of manufacturer
- Small
- Mid-sized
- Large
Key Geographical Region
- North America
- Europe
- Asia-Pacific and Rest of the World
The Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030 report features the following companies, which we identified to be key players in this domain:
- Agilent Technologies
- Ajinomoto Bio-Pharma Services
- BioSpring
- CordenPharma
- Integrated DNA Technologies
- Kaneka Eurogentec
- LGC Biosearch Technologies
- Microsynth
- Nitto Denko Avecia
- Sigma Aldrich
- Thermo Fisher Scientific
- Trilink Biotechnologies
Table of Contents
- Preface
- Executive Summary
- Introduction
- Market Landscape: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
- Market Landscape: Oligonucleotide Manufacturers (Therapeutic Applications)
- Company Competitiveness Analysis: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
- Company Competitiveness Analysis: Oligonucleotide Manufacturers (Therapeutic Applications)
- Company Profiles: Oligonucleotide Manufacturers (Research and Diagnostic Applications)
- Company Profiles: Oligonucleotide Manufacturers (Therapeutic Applications)
- Partnerships and Collaborations
- Recent Expansions
- Clinical Trial Analysis
- Capacity Analysis
- Demand Analysis
- Market Sizing and Opportunity Analysis
- Swot Analysis
- Survey Analysis
- Executive Insights
- Concluding Remarks
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Neoantigens Market is Projected to Reach USD 3 billion by 2030
The use of neoantigens in therapy has demonstrated the ability to elicit a strong T cell mediated immune response. Several therapy candidates are being investigated both as monotherapies and in combination with various immune checkpoint inhibitors, such as atezolizumab, durvalumab, ipilimumab, and nivolumab. Of these, certain pipeline candidates have already entered mid to late-stage (phase II and above) trials and are anticipated to enter the market over the next 5-10 years.
The USD 3 billion (by 2030) financial opportunity within the Neoantigens Market has been analyzed across the following segments:
Type of target disease indication
- Bone cancer
- Colorectal cancer
- Gynecological cancer
- Non-small cell lung cancer
- Renal cell carcinoma
- Other cancers
Type of neoantigens
- Personalized neoantigens
- Off-the-shelf neoantigens
Type of immunotherapy
- Dendritic cell vaccines
- DNA / RNA-based vaccines
- Protein / peptide-based vaccines
- TIL-based therapies
Route of administration
- Intradermal
- Intravenous
- Subcutaneous
- Other routes
Key geographical regions
- North America
- Europe
- Rest of the World
The report features inputs from eminent industry stakeholders, according to whom neoantigen targeted therapies are expected to be the next big step in cancer immunotherapy. Similar to CAR-T cell therapies, these therapies have, so far, demonstrated significant therapeutic potential and promising clinical outcomes.
The report includes detailed transcripts of discussions held with the following experts:
- Gabriel Nistor (Chief Science Officer, AIVITA Biomedical)
- Ella Sorani (Vice President Research and Development, BioLineRx)
- Heinz Lubenau (Chief Operating Officer & Co-founder, VAXIMM)
The Neoantigen Targeted Therapies, 2019-2030 report features the following companies, which we identified to be key players in this domain:
- Bavarian Nordic
- Genocea Biosciences
- Gradalis
- Immunicum
- Immunovative Therapies
- Iovance Biotherapeutics
- Medigene
- Neon Therapeutics
- Precision Biologics
- Vaxon Biotech
Table of Contents
- Preface
- Executive Summary
- Introduction
- Market Overview
- Company Profiles: Neoantigen Targeted Therapies
- Publication Analysis
- Patent Analysis
- Partnerships and Collaborations
- Funding and Investment Analysis
- Market Forecast and Opportunity Analysis
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
For more information, please click on the following link:
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Microbiome Therapeutics (Tx) Market And Diagnostics (Dx) Market is Expected to Reach 4 billion by 2030
The concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine.
Despite having captured the interest of several venture capital firms and big pharma players, no microbiome-based therapeutic has been officially approved by an authorized medical product regulator. However, the current development pipeline of microbiome therapeutics has several promising candidates that are likely to result in commercial success stories soon.
The USD 4 billion (by 2030) financial opportunity within the Microbiome Therapeutics (Tx) Market And Diagnostics (Dx) Markets, has been analyzed across the following segments:
Type of Therapy (Tx)
• Prescription Drug
• Prebiotics
Type of Molecule (Tx)
• Small Molecules
• Biologics
Target Indication (Tx+Dx)
• Acne Vulgaris
• Atopic Dermatitis
• Clostridium difficile Infection
• Colorectal Cancer
• Crohn’s Disease
• Diabetes
• Irritable Bowel Syndrome
• Lactose Intolerance
• Lung Cancer
• Nonalcoholic steatohepatitis (NASH)
• Obesity
• Ulcerative colitis
Therapeutic Area (Tx+Dx)
• Autoimmune Disorders
• Dental Disorders
• Digestive and Gastrointestinal Disorders
• Dermatological Disorders
• Infectious Disease
• Metabolic Disorders
• Oncology
• Others
Key Geographical Regions (Tx+Dx)
• North America
• Europe
• Asia-Pacific and Rest of the World
The Human Microbiome Market, 2019-2030 report features the following companies, which we identified to be key players in this domain:
Key Players:
• 4D Pharma
• Armata Pharmaceuticals
• Evelo Biosciences
• Rebiotix (Acquired by Ferring Pharmaceuticals)
• Seres Therapeutics
• Vedanta Biosciences
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Microbiome Therapeutics: Market Landscape
5. Company and Drug Profiles
6. Microbiome Diagnostics: Market Landscape
7. Fecal Microbiota Therapy (FMT)
8. Attractiveness Competitiveness (AC) Matrix
9. Microbiome Related Initiatives of Big Pharmaceutical Players
10. Start-up Health Indexing
11. Key Therapeutics Areas
12. Funding and Investment Analysis
13. Contract Services for Microbiome Therapeutics
14. Big Data and Microbiome Therapeutics
15. Microbiome Therapeutics: Market Forecast and Opportunity Analysis
16. Microbiome Diagnostics: Market Forecast and Opportunity Analysis
17. Fecal Microbiota Therapies: Market Forecast and Opportunity Analysis
18. Case Study: Microbiome-based Products in Other Industries
19. Concluding Remarks
20. Executive Insights
21. Appendix I: Tabulated Data
22. Appendix II: List of Companies and Organizations
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
 Market And Diagnostics (Dx) Market is Expected to Reach 4 billion by 2030 )
Ophthalmic Drugs Contract Manufacturing Market Report – Industry Size, Share, Trends, Growth and Forecast Till 2030
Owing to various reasons, such as growing manufacturing demand, need for specialized facilities, equipment and operational expertise, and high costs of development associated with certain drugs / therapies, a number of ophthalmic drug developers have demonstrated a preference to outsource certain aspects of drug development and production operations to contract service providers.
The USD 1.7 billion financial opportunity (by 2030) within the Ophthalmic Drugs Contract Manufacturing Market has been analyzed across the following segments:
Type of product
• Ophthalmic API
• Ophthalmic drug FDF
Type of FDF manufactured
• Solid
• Semi-solid
• Liquid / suspension
Type of primary packaging
• Ampoule / vial
• Glass / plastic bottle
• Ointment tube
• Blister packing
• Other forms
Scale of manufacturing
• Clinical
• Commercial
Company size
• Small
• Mid-sized
• Large
• Very large
Target disease indication
• Age-related macular degeneration
• Dry eye
• Glaucoma
• Other disease segments
Key geographical regions
• North America (US, Canada and Mexico)
• Europe (UK, Germany, France, Spain, Italy and rest of Europe)
• Asia-Pacific (India, China, Japan, Australia and rest of Asia-Pacific)
• Rest of the world
The Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030 report features the following companies, which we identified to be key players in this domain:
• Akorn
• Akums
• Bal Pharma
• Catalent
• Cayman Chemical
• Entod Pharmaceuticals
• Farmigea
• Glenmark Pharmaceuticals
• Indiana Ophthalmics
• Lomapharm
• Medichem
• Pillar5 Pharma
• Recipharm
• Salvat
• Sterling Pharmaceutical Services
• Sunways India
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Current Market Landscape
5. Company Competitiveness Analysis
6. Ophthalmic Drugs Contract Manufacturing in North America: Company Profiles
7. Ophthalmic Drugs Contract Manufacturing in Europe: Company Profiles
8. Ophthalmic Drugs Contract Manufacturing in Asia-Pacific: Company Profiles
9. Clinical Trial Analysis
10. Capacity Analysis
11. Demand Analysis
12. Market Forecast
13. Case Study: Comparison of Small Molecule and Large Molecule Ophthalmic Drugs / Therapies
14. SWOT Analysis
15. Survey Analysis
16. Executive Insights
17. Future Growth Opportunities
18. Appendix 1: List of Ophthalmic Medical Device Contract Manufacturers
19. Appendix 2: Tabulated Data
20. Appendix 3: List of Companies and Organizations
For more information, please click on the following link:
https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
